Recent Updates
Recently added Catalysts
CELC Positive Sentiment

Celcuity to Participate in the BTIG Virtual Biotechnology Conference 2023

Monday, July 31, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Celcuity Inc. has announced its participation in the BTIG Virtual Biotechnology Conference scheduled for August 7-8, 2023. The company's CEO, Brian Sullivan, will engage in one-on-one meetings during the event. This involvement underscores Celcuity's commitment to advancing its pipeline of targeted therapies for oncology. The conference presents an opportunity for increased visibility and potential collaborations in the biotechnology sector.
Price reaction · baseline $10 (2023-07-28 close) · 1 other CELC headline(s) in the window, move may be shared
day 0 close · peak
-1.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a significant biotechnology conference highlights company engagement.
  • One-on-one meetings may lead to valuable networking and partnership opportunities.
  • Focus on targeted therapies for oncology positions the company in a growing market.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+27%
120-day peak, hindsight
Typical move
14.9%
average across 6 past catalysts
Cash runway
~41 mo
Minimal dilution risk
Lead asset
Gedatolisib
Phase 3 · Breast Cancer

Full Press Release Details

MINNEAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will participate in one-on-one meetings at the BTIG Virtual Biotechnology Conference being held on August 7-8, 2023.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
Robert Uhl, robert.uhl@westwicke.com

Frequently Asked Questions

What is the focus of Celcuity Inc.?

Celcuity Inc. specializes in developing targeted therapies for oncology.

Who is Brian Sullivan?

Brian Sullivan is the Chairman, CEO, and Co-founder of Celcuity Inc.

When is the BTIG Virtual Biotechnology Conference?

The BTIG Virtual Biotechnology Conference is scheduled for August 7-8, 2023.

How can I contact Celcuity for inquiries?

Inquiries can be directed to Brian Sullivan or Vicky Hahne via email.

ShareAdd on Google
Tags: CELC Viatris Investor Conferences Healthcare Celcuity biotechnology oncology conference
Last updated: Jul 31, 2023

Biotech snapshot

Cash runway
$754M liquidity · $18M/mo burn
~41 mo
Minimal dilution risk
Lead asset
GedatolisibPhase 3
Breast Cancer →

Catalyst track record

+27%
best trade around CELC's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for CELC.

See every catalyst's timing & PoA →